Clinical Study Number | 9.182 |
---|---|
Study Indication | Stroke |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | IV |
Study Title |
Prospective, randomised, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of stroke onset on an acute stroke unit, and Aggrenox® b.i.d. when started after a 7-day therapy with ASA 100 mg once daily outside of an acute stroke unit, in symptomatic ischaemic stroke patients over a three months treatment period (EARLY) - An exploratory study |
Study Document | Trial synopsis 9.182_DS_DR english |
Clinical Study Number | 9.178 |
---|---|
Study Indication | Stroke |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | III |
Study Title |
Japanese Aggrenox Stroke Prevention vs. Aspirin Programme (JASAP): Phase III study to evaluate the preventive effect of recurrent cerebral infarction and safety of Aggrenox (a combination drug containing sustained-release dipyridamole 200 mg and acetylsalicylic acid 25 mg) twice daily compared with acetylsalicylic acid 81 mg once daily |
Study Document | Trial Synopsis 9.178_CO english |
Clinical Study Number | 9.169 |
---|---|
Study Indication | Coronary Artery Disease |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | IV |
Study Title |
A randomised, crossover study comparing the biochemical and platelet effects of modified-release dipyridamole/aspirin (200mg/25 mg bd; Asasantin Retard®) with aspirin (75 mg qd) in coronary artery disease patients with aspirin resistance manifesting as persistent thromboxane formation. |
Study Document | Trial synopsis 9.169_CO english |
Clinical Study Number | 9.155 |
---|---|
Study Indication | Stroke |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | III |
Study Title |
Tolerability of a Four Weeks Treatment with Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial among Taiwanese Patients with Previous TIAs or Ischemic Stroke |
Study Document | Trial synopsis 9.155 english |
Clinical Study Number | 9.159 |
---|---|
Study Indication | Stroke |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | III/IV |
Study Title |
PRoFESS – Prevention Regimen For Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox® vs. clopidogrel, with and without Micardis® |
Study Document | Trial synopsis 9.159_DS_CO english |
Clinical Study Number | 9.197 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Drug-Drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox ® Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-Label, Randomized, Crossover Study) |
Study Document | Trial synopsis 9.197_CO english |
Clinical Study Number | 9.127 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Pharmacokinetics and safety of Asasantin extended release (RAD-SP) 200/25 mg capsules b.i.d. in randomised, double-blind, placebo controlled study in Japanese healthy male volunteers |
Study Document | Trial synopsis 9.127_CO english |
Clinical Study Number | 9.130 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
A randomised, two-period, cross over trial to compare the effects of acetylsalicylic acid (75 mg/day) with the combination of acetylsalicylic acid (25 mg) + modified-release dipyridamole (200 mg) (bd) on serum thromboxane B2 formation and platelet aggregation in healthy volunteers |
Study Document | Trial synopsis 9.130_CO english |
Clinical Study Number | 9.131 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Tolerability of a two week treatment with Asasantin extended release 200/25 mg capsules b.i.d, compared to reduced dose during the first week of treatment in a double-blind, randomised, placebo controlled parallel group comparison trial in healthy female and male subjects |
Study Document | Trial synopsis 9.131_CO english |
Clinical Study Number | 9.136 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Impact of food on pharmacokinetics and pharmacodynamics of Asasantin extended release (ER) 200/25 mg capsules b.i.d. in a randomized, open, 2-way cross-over study in healthy subjects. |
Study Document | Trial synopsis 9.136_CO english |
Clinical Study Number | 9.138 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Comparison of pharmacokinetics of dipyridamole in Asasantin extended release (ER) 200/25 mg capsules bid and in a combination of Persantin immediate release tablets (100 mg qid) and ASA tablets (25 mg bid) in an open, randomized, 2-way crossover study in healthy subjects. |
Study Document | Trial synopsis 9.138_CO english |
Clinical Study Number | 9.142 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Mechanism of dipyridamole action in platelets: in-vivo study with healthy volunteers |
Study Document | Trial synopsis 9.142 english |
Clinical Study Number | 9.144 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
A double-blind, randomised, 3-way cross-over study to compare the pharmacokinetics of dipyridamole in three different Asasantin ER extended release (ER) 200 mg dipyridamole/25 mg ASA formulations in healthy male and female volunteers. |
Study Document | Trial synopsis 9.144 english |
Clinical Study Number | 9.146 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | IV |
Study Title |
Comparison of pharmacokinetics of dipyridamole administered as Aggrenox® (dipyridamole extended release plus aspirin) capsule versus dipyridamole immediate release plus aspirin following alteration of stomach pH by the prior administration of a proton-pump inhibitor: An open-label 2-way randomized cross-over study in healthy male and female subjects age 40-65. |
Study Document | Trial synopsis 9.146_CO english |
Clinical Study Number | 9.149 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Bioequivalence of a new Asasantin capsule formulation (extended release combination 200 mg Dipyridamole/25 mg ASA) compared to the commercially available Asasantin capsule formulation (Aggrenox®; extended release combination 200 mg dipyridamole/25 mg ASA) following multiple oral administration at steady state after a run-inphase (Persantine ER BID for 2 days each: 25 mg, 50 mg, 100 mg; 150 mg [Persantine®]; 200 mg Dipyridamole/25 mg ASA [AsasantinER]) - an open label, randomized, multiple-dose, two-way crossover,change-over study in healthy male and female volunteers. |
Study Document | Trial synopsis 9.149 english |
Clinical Study Number | 9.158 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Bioavailability of dipyridamole after Asasantin (extended release 200 mg dipyridamole/25mg ASA) in 3 experimental formulations (given b.i.d. over 3 or 5 days, respectively) relative to the standard formulation in 16 healthy female and male subjects. Intraindividual comparison, randomised, open. |
Study Document | Trial synopsis 9.158 english |
Clinical Study Number | 9.163 |
---|---|
Study Indication | Healthy |
Product | AGGRENOX ® |
Generic Name | Dipyridamole + Acetylsalicylic acid |
Lab Code | |
Clinical Phase | I |
Study Title |
Bioavailability of dipyridamole of Asasantin p.o. (extended release 200 mg dipyridamole/25 mg ASA) in three experimental formulations (given BID over 3 days each) relative to the standard formulation aftera run-in phase (Persantine ER BID for 2 days each: 25 mg, 50 mg,100 mg; 150 mg [Persantine®]; 200 mg Persantine /25 mg ASA [Asasantin ER] in healthy male subjects. Four-way, change-over,randomised, open |
Study Document | Trial synopsis 9.163 english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.